BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23406663)

  • 1. Blood clotting activation analysis for preoperative differentiation of benign versus malignant ovarian masses.
    Amirkhosravi A; Bigsby G; Desai H; Rivera-Amaya M; Coll E; Robles-Carrillo L; Faust P; Waters A; Meyer T; Reyes E; Langer F; Francis JL
    Blood Coagul Fibrinolysis; 2013 Jul; 24(5):510-7. PubMed ID: 23406663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer.
    Claussen C; Rausch AV; Lezius S; Amirkhosravi A; Davila M; Francis JL; Hisada YM; Mackman N; Bokemeyer C; Schmalfeldt B; Mahner S; Langer F
    Thromb Res; 2016 May; 141():39-48. PubMed ID: 26967531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma tissue factor antigen in localized prostate cancer: distribution, clinical significance and correlation with haemostatic activation markers.
    Langer F; Chun FK; Amirkhosravi A; Friedrich M; Leuenroth S; Eifrig B; Bokemeyer C; Francis JL
    Thromb Haemost; 2007 Mar; 97(3):464-70. PubMed ID: 17334515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D-dimer as a tumor marker in pre-operative assessment of adnexal masses.
    Worasethsin P; Narkwichean A
    J Med Assoc Thai; 2013 Nov; 96(11):1395-400. PubMed ID: 24428087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
    Gadducci A; Baicchi U; Marrai R; Ferdeghini M; Bianchi R; Facchini V
    Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.
    Cooper BC; Ritchie JM; Broghammer CL; Coffin J; Sorosky JI; Buller RE; Hendrix MJ; Sood AK
    Clin Cancer Res; 2002 Oct; 8(10):3193-7. PubMed ID: 12374688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating microparticles in patients with benign and malignant ovarian tumors.
    Rank A; Liebhardt S; Zwirner J; Burges A; Nieuwland R; Toth B
    Anticancer Res; 2012 May; 32(5):2009-14. PubMed ID: 22593480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
    Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
    Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-marker combinations for preoperative discrimination of benign and malignant ovarian masses.
    Freydanck MK; Laubender RP; Rack B; Schuhmacher L; Jeschke U; Scholz C
    Anticancer Res; 2012 May; 32(5):2003-8. PubMed ID: 22593479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum C-reactive protein in the differential diagnosis of ovarian masses.
    Hefler-Frischmuth K; Hefler LA; Heinze G; Paseka V; Grimm C; Tempfer CB
    Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):65-8. PubMed ID: 19619929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The assessment of the dependence between antigen CA 125 and nicotinism in patients with benign ovarian tumors including endometrial cysts].
    Posadzka E; Jach R; Babczyk D; Knafel A; Pityński K
    Przegl Lek; 2014; 71(6):319-22. PubMed ID: 25344972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
    Serin IS; Tanriverdi F; Yilmaz MO; Ozcelik B; Unluhizarci K
    Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study.
    Van Calster B; Valentin L; Van Holsbeke C; Zhang J; Jurkovic D; Lissoni AA; Testa AC; Czekierdowski A; Fischerová D; Domali E; Van de Putte G; Vergote I; Van Huffel S; Bourne T; Timmerman D
    Cancer Epidemiol Biomarkers Prev; 2011 Nov; 20(11):2420-8. PubMed ID: 21908724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Major obstetric haemorrhage: monitoring with thromboelastography, laboratory analyses or both?
    Karlsson O; Jeppsson A; Hellgren M
    Int J Obstet Anesth; 2014 Feb; 23(1):10-7. PubMed ID: 24342222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer.
    Hron G; Kollars M; Weber H; Sagaster V; Quehenberger P; Eichinger S; Kyrle PA; Weltermann A
    Thromb Haemost; 2007 Jan; 97(1):119-23. PubMed ID: 17200778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
    Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
    Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian masses in children and adolescents - an analysis of 521 clinical cases.
    Zhang M; Jiang W; Li G; Xu C
    J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):e73-7. PubMed ID: 24157281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D-dimer, Fibrinogen and Tumor Marker Levels in Patients with benign and Malignant Ovarian Tumors.
    Farzaneh F; Salimnezhad M; Hosseini MS; Ashraf Ganjouee T; Arab M; Talayeh M
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4263-4268. PubMed ID: 38156862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study.
    Sehouli J; Akdogan Z; Heinze T; Könsgen D; Stengel D; Mustea A; Lichtenegger W
    Anticancer Res; 2003; 23(2A):1115-8. PubMed ID: 12820357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.